*Average returns of all recommendations since inception. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. It has real products. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. How long might it take for Ocugen to win full FDA approval for Covaxin? Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Like other life sciences companies involved in Covid-19 vaccine. At the beginning of 2020, Ocugen shares were trading at just 47 cents. The Motley Fool has a disclosure policy. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Typically, I care little about financials with biotechs. But there is no question some big-name stocks performed better than others along the way. Keith Speights owns shares of Pfizer. That doesnt mean success is guaranteed. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing.